乌鸦传媒

Nephrology

<乌鸦传媒 class='mpt-top_cat_title_description'>News, opinions and meeting coverage in nephrology.

<乌鸦传媒>CardioBrief: Int'l Experts Call Sodium Guidelines Far Too Restrictive

Conclusion: research more, recommend less

<乌鸦传媒>ECC Roundup: Breast Conservation Benefit Varies by Age

And other reports from the European Cancer Congress

<乌鸦传媒>Subclavian TAVR Safe When Femoral Access Is Risky

Trial analysis shows similar morbidity, mortality

<乌鸦传媒>SAVR Beats Expectations in Intermediate Risk Trial

Lower mortality than surgical risk score predicted in PARTNER 2A

<乌鸦传媒>FDA Warns on MRI in Patients with Implantable Pumps

Medication, mechanical issues may follow exposure

<乌鸦传媒>Novartis Pulls Out of Controversial Entresto Contest

Cardiologists named to review panel had quit

<乌鸦传媒>Nephrology Training Programs a Hard Sell

Pay, lifestyle issues may hamper interest in the specialty

<乌鸦传媒>Amyloidosis Treatments Miss the Heart of the Problem

Only modest improvement in end organ function

<乌鸦传媒>CMS to Offer Billing Code for Heart Failure Specialists

Should eliminate denials for appearance of double-billing

<乌鸦传媒>Oral Treatment for T2D Tied to Renal Protection

SGLT2 inhibitor shows favorable effect on eGFR

<乌鸦传媒>Quick Steroid Withdrawal Works in Post-Transplant Diabetes

Incidence dropped from 39% to about 24%

<乌鸦传媒>Opioid Rx Linked to Higher Mortality in Dialysis Patients

Risks for hospitalization, dialysis discontinuation also higher

<乌鸦传媒>Lowering Urate Helps Renal Function

Most improvement seen in stage 3 chronic kidney disease

<乌鸦传媒>New Hospital Care Model Cut Readmissions, Boosted Satisfaction

Specialists urged to reconnect with generalist roots

<乌鸦传媒>Nephrologists at Kidney Week Blast Recertification Process

Consensus: stop making it a high-stakes exam

<乌鸦传媒>Trial: No Benefit for High-Dose Diuretic in Acute HF

But phase II results might not be the final word

<乌鸦传媒>AHA: No Pump Thrombosis With Next-Gen LVAD?

Better outcomes in HeartMate 3 trial hinged on fewer malfunctions

<乌鸦传媒>AHA: Real World TAVR Is All About Patient Selection

Intermediate risk is a moving target

<乌鸦传媒>AHA: Long-Term Benefit in HF Patients Elusive for Novel Vasodilator

Investigational drug ularitide had no effect on mortality or clinical outcomes

<乌鸦传媒>TCT: TAVR Holds Up Pretty Well Over Time

Also, 2-year data confirm lasting improvements in QoL

<乌鸦传媒>TCT: Embolic Protection Flops for TAVR

New brain lesions or clinical strokes unaffected in SENTINEL trial

<乌鸦传媒>CardioBrief: Impella No Better Than IABP in Cardiogenic Shock

Underpowered IMPRESS trial shows no mortality benefit

<乌鸦传媒>U.S. Obesity Crisis: Is the Wrong Omega-X Mix Responsible?

Ratio of omega-6 to omega-3 in Western diet is 16:1

<乌鸦传媒>Pearls From: Roxana Mehran, MD

Interventional cardiologist discusses acute kidney injury reduction

<乌鸦传媒>Slow Medicine: Is 'Hypertensive Urgency' Outdated?

No need to over-react to a common dx that's not tied to major CV events

<乌鸦传媒>HFSA: Clinical Benefits Tied To Lung Monitoring Persist

HF rehospitalization, deaths remain reduced up to 4.5 years

<乌鸦传媒>Cardiac Myosin Activator Shows Promise for LV Function

'More hands pulling on the rope'

<乌鸦传媒>HFSA: Treat to NT-proBNP Target Flops in Trial

Outcomes no better with treatment aimed at 30% reduction

<乌鸦传媒>HFSA: Did LAP Monitoring Cut HF Rehospitalizations?

LAPTOP-HF investigators tried to make sense of terminated study

<乌鸦传媒>Longer-Term Home Use Safe for Artificial Pancreas System

3-month study might pave way to FDA clearance

<乌鸦传媒>Switching GLP-1 For DPP-4 Improves Net T2D Outcomes

Victoza bests Januvia for combo therapy on A1c, weight, hypoglycemia composite

<乌鸦传媒>How Sweet: Sugar Industry Made Fat the Villain

Harvard researchers received sugar industry money to write a NEJMreview

<乌鸦传媒>MedPAC Looks at Ways to Adjust Misvalued Services

Commission debates grouping CPT codes into families

<乌鸦传媒>CardioBrief: Cardiologists Give SPRINT Thumbs Down

Trial should not be used in guidelines to lower blood pressure targets

<乌鸦传媒>ESC: No Mortality Benefit With ICD in Nonischemic HF

Eleven fewer deaths over 5 years

<乌鸦传媒>Is 2018 the Year of the Bionic Pancreas?

Two experts review the state of closed-loop systems for type 1 diabetes

<乌鸦传媒>FDA Panel Splits on Expanded Jardiance Indication

Questions raised about key trial

<乌鸦传媒>Are Expensive Diabetes Drugs Worth It?

Jardiance and Victoza improve hard outcomes, but at a hefty cost

<乌鸦传媒>301 People Charged With $900 Million in False Medicare Billings

Largest sweep since government fraud team began in 2007

<乌鸦传媒>Mixed Findings on High Birth Weight, CV Risk Factors

Some markers of cardiovascular health better with high birth weight

鈥�

35

鈥�